FBIO Stock Overview
A biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Fortress Biotech, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.87 |
| 52 Week High | US$10.65 |
| 52 Week Low | US$1.24 |
| Beta | 1.55 |
| 1 Month Change | 6.86% |
| 3 Month Change | 6.86% |
| 1 Year Change | -75.63% |
| 3 Year Change | -96.67% |
| 5 Year Change | -93.07% |
| Change since IPO | -98.87% |
Recent News & Updates
Recent updates
There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise
Dec 29
There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding
Aug 18Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients
Aug 11David Jin is the new finance chief of Fortress Biotech
Jul 22Is Fortress Biotech (NASDAQ:FBIO) Using Debt Sensibly?
Jan 11Fortress Biotech (NASDAQ:FBIO) Has Debt But No Earnings; Should You Worry?
Sep 28Does Fortress Biotech (NASDAQ:FBIO) Have A Healthy Balance Sheet?
Jun 04Is Fortress Biotech (NASDAQ:FBIO) Using Too Much Debt?
Mar 04When Will Fortress Biotech, Inc. (NASDAQ:FBIO) Turn A Profit?
Feb 06Read This Before Buying Fortress Biotech, Inc. (NASDAQ:FBIO) Shares
Jan 11
Fortress Biotech founded Cyprium's CUTX-101 nabs accelerated review for copper metabolism disorder
Dec 15Is Fortress Biotech, Inc. (NASDAQ:FBIO) Popular Amongst Insiders?
Dec 15Health Check: How Prudently Does Fortress Biotech (NASDAQ:FBIO) Use Debt?
Nov 19Fortress Biotech EPS misses by $0.02, misses on revenue
Nov 09Shareholder Returns
| FBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 7.5% | 0.07% | -0.2% |
| 1Y | -75.6% | 6.9% | 28.2% |
Return vs Industry: FBIO underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: FBIO underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| FBIO volatility | |
|---|---|
| FBIO Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: FBIO's share price has been volatile over the past 3 months.
Volatility Over Time: FBIO's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 186 | Lindsay Rosenwald | www.fortressbiotech.com |
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea.
Fortress Biotech, Inc. Fundamentals Summary
| FBIO fundamental statistics | |
|---|---|
| Market cap | US$38.08m |
| Earnings (TTM) | -US$62.55m |
| Revenue (TTM) | US$85.11m |
0.4x
P/S Ratio-0.6x
P/E RatioIs FBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FBIO income statement (TTM) | |
|---|---|
| Revenue | US$85.11m |
| Cost of Revenue | US$133.10m |
| Gross Profit | -US$47.98m |
| Other Expenses | US$14.57m |
| Earnings | -US$62.55m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.25 |
| Gross Margin | -56.38% |
| Net Profit Margin | -73.49% |
| Debt/Equity Ratio | -1,738.4% |
How did FBIO perform over the long term?
See historical performance and comparison